gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LQDAHealthcarePharmaceuticals

Liquidia Corporation Common Stock (LQDA)

$47.38+12.27%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$48.72▲ 93.16% in range
Nov 3, 2025Low $25.22 · High $91.03Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Liquidia closed at $47.38 on Nov 4, up 12.27%, 48.0% below its 52-week closing high. Volume of 4.8M shares was 0.98× its 20-day average (close to normal).

Split-adjusted performance: +82.9% over one month, +12.4% over six months, +87.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $171.68M, up 1842.7% from a year earlier, with a net margin of 43.5%.

Short interest was 17.3M shares at the Oct 15 settlement, up 36.9% from the prior report (26.2% of float, 2.0 days to cover).

Market cap$4.24B89.5M shares
Revenue · quarter$171.7M+1842.7% YoY
Diluted EPS$0.74—
P/E · TTM30.6×P/S 9.4×
Net margin43.5%Gross 93.3%
Dividend yieldNone
52-week range25.22 – 91.03−48.0% from high
Volume4.8M0.98× 20-day avg
Volatility · 60d191.5%Annualised
Short % of float26.2%2.0 days to cover
Net cash$108.1MCash $284.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.6%1M +82.9%3M −47.0%6M +12.4%YTD +37.4%1Y +87.9%3Y +659.3%5Y +1223.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum78
Revenue growth96
Net margin93
Value (low P/E)36
Size89

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short17.3M+36.9% vs prior
Days to cover2.0Settled Oct 15
% of float26.2%
Short vol. 10d51.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LQDALiquidia$47.38+12.27%+12.4%+1842.7%43.5%30.6$4.24B
ARQTArcutis Biotherapeutics$34.05+6.41%+40.9%+59.3%11.6%150.1$4.28BCompare
DFTXDefinium Therapeutics$32.70−2.13%+39.6%———$4.39BCompare
EWTXEdgewise Therapeutics$37.53−0.40%+1.5%———$4.08BCompare
ABCLAbCellera Biologics$12.28+0.82%+143.7%−76.3%−1368.6%—$3.98BCompare
TNGXTango Therapeutics$23.18+0.04%−1.9%−100.0%——$3.91BCompare
XENEXenon Pharmaceuticals$39.19+2.51%−33.1%———$3.80BCompare
PBLSParabilis Medicines$30.36+3.79%——−45239.9%—$3.75BCompare
DNTHDianthus Therapeutics$85.81+3.76%−5.1%+294.3%−6598.6%—$4.80BCompare

News about Liquidia

All news →
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 26, 2026▼ NegativeLQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelZacks Investment Research · Oct 14, 2026▼ NegativeLIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the FirmGlobeNewswire Inc. · Oct 7, 2026▼ NegativeLiquidia Stock Plunges 57% on UTHR Patent Litigation SetbackZacks Investment Research · Oct 1, 2026▼ NegativeUTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%Zacks Investment Research · Oct 1, 2026▼ Negative

Quick answers

What does Liquidia do?
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles.
What is LQDA's market cap?
$4.24B, based on the Nov 4 close of $47.38.
What is LQDA's P/E ratio?
30.6× trailing-twelve-month earnings of $138.61M.
Does Liquidia pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LQDA is sold short?
17.3M shares, 26.2% of float, as of Oct 15, 2026.
What sector is LQDA in?
Healthcare, in the Pharmaceuticals industry.

About Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

HQ: Morrisville, NC216 employeesListed Jul 26, 2018liquidia.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology